Free PTCB MTM Exam Flashcards

Strength is the amount of active ingredient in a unit or concentration, such as 500 mg per tablet. Dose is the amount the patient is instructed to take at one time, such as two 500 mg tablets for a 1,000 mg dose.

The form—tablet, capsule, liquid, patch, inhaler, or another form—affects how the drug is measured and administered. The same drug name and strength can still require different instructions when the dosage form differs.

It describes how a medication enters or is applied to the body, such as oral, topical, inhaled, ophthalmic, or subcutaneous. A route mismatch is clinically important and should be escalated for review.

Record and communicate the exact product requirement, such as refrigeration, protection from light, or special handling. Do not assume that all products with the same active ingredient have identical storage instructions.

Instructions such as take with food, do not crush, separate from another product, or use a specific device can affect safety and effectiveness. A missing or contradictory instruction should be flagged for pharmacist review.

It indicates how long the medication is intended to be used. Comparing the intended duration with refill history and the current list can reveal an unintended continuation, an early stop, or a gap in therapy.

Identify and document the possible cost-saving opportunity, then route it for pharmacist, prescriber, and plan review as appropriate. Similar purpose or dosage form does not authorize the technician to make a clinical substitution.

Use “high blood pressure.” Plain language can improve understanding while the formal term remains useful in the clinical record.

Use “high blood sugar.” Confirm understanding rather than assuming the patient recognizes the medical term.

An allergy involves an immune-mediated reaction; an intolerance is an unwanted effect that is not an immune allergy. Record the patient's specific reaction instead of replacing it with a vague label.

It describes how closely a patient's medication use follows the agreed regimen. It should be explored without blame because cost, access, adverse effects, misunderstanding, and daily routine can all create barriers.

The indication links the product to the condition or goal it is intended to address. A missing or unclear purpose can expose duplicate therapy, a gap in therapy, or a need for pharmacist clarification.

Include prescription drugs, nonprescription products, vitamins, herbals, and supplements the patient actually uses. Products outside the pharmacy claims record can still affect therapy and interactions.

Factors such as tobacco or alcohol use, living situation, transportation, health literacy, and ability to pay can affect medication safety, access, and adherence. Collect relevant facts and route clinical implications to the pharmacist.

It helps the care team identify what has been received and possible preventive-care gaps. The technician can gather and document history; clinical recommendations should follow the applicable protocol and qualified-provider review.

A side effect is an unintended effect of a drug and is not automatically immune-mediated. Document the exact symptom, severity, and timing so the pharmacist can assess whether it represents an expected effect, intolerance, allergy, or another problem.

Clarify how the patient is actually taking the medication and ask about barriers in a neutral way. Do not label the patient or recommend a therapy change before the pharmacist evaluates the information.

Cost may lead to delayed fills, skipped doses, dose stretching, or complete discontinuation. Document the barrier and route possible benefit, formulary, assistance, or therapeutic options for appropriate review.

It is a potentially missing medication or period of coverage for an identified treatment need. It is a signal for assessment, not permission for a technician to diagnose or add therapy independently.

They are clinical measures that can help the pharmacist assess treatment goals and safety. A technician should accurately collect available values and dates and escalate abnormal or unclear results rather than interpret them beyond role and policy.

Days' supply = quantity dispensed ÷ units used per day. Confirm that the directions describe a fixed daily amount before applying the formula.

30 days. The patient uses 2 tablets per day, so 60 ÷ 2 = 30.

PDC = covered days in the measurement period ÷ total days in that period, usually expressed as a percentage. A calendar day is counted as covered or not covered for the drug or class being measured.

The same calendar day is not counted more than once. Coverage may be carried forward under the measure's rules, but PDC cannot exceed 100% for the measurement period.

75%. Divide 90 by 120, then multiply by 100.

PDC estimates whether medication was available during the period. It does not prove that the patient took every dose, so the result should guide follow-up rather than be treated as direct observation.

Compare drug name, strength, dose, dosage form, route, frequency, purpose, and the patient's reported use against available sources. Resolve omissions, duplicates, and conflicting entries through the defined review process.

It is patient-centered, specific, understandable, and clear about the action or follow-up. It should not silently convert an unresolved clinical recommendation into a direction for the patient to change therapy.

Verify the patient and encounter, medications reviewed, identified issues, recommendations or referrals, patient-facing records, responsible parties, and follow-up plan. Missing or conflicting information should remain open for correction.

Patient, provider, service date, service type, time or units, and related documentation must support the submitted service under the applicable payer rules. A missing or inconsistent field can delay payment or create an inaccurate claim.

The prescribed amount is unexpectedly high, low, or otherwise inconsistent with the intended regimen. Do not normalize or correct it by assumption; verify the source and escalate for clinical review.

The product strength does not match the intended strength, even if the drug name is correct. Because strength and dose are different fields, both must be checked independently.

The selected medication is not the intended drug. Similar names, adjacent menu choices, and mismatched indications are warning cues that require verification rather than assumption.

The ordered route does not match the intended method of administration, such as oral versus ophthalmic. Route errors can cause serious harm and should be escalated promptly.

Mark the discrepancy, compare the authoritative source documents, and route it for clarification. Choosing the most familiar schedule without verification can perpetuate an incorrect direction.

A required dose amount or usable dosing instruction is absent. The record is incomplete and should not be made to look complete by inventing a dose from prior history.

Two therapies with overlapping effects may be intentional, but they can also increase adverse effects or indicate an unreconciled list. Confirm actual use and refer the potential duplication for pharmacist assessment.

Document the exact products and concern, determine whether immediate escalation is required under policy, and send it to the pharmacist or other qualified provider. Do not tell the patient to stop or change therapy independently.

To improve medication use and therapeutic outcomes while reducing medication-related risks. MTM organizes review, patient information, action planning, intervention, documentation, and follow-up around those goals.

A structured review of the patient's medications to identify and address medication-related problems and opportunities. It supplies the clinical foundation for the other MTM service elements.

It gives the patient an accurate, current list of medications and how they are used. The record should be understandable and updated when the regimen changes.

It gives the patient clear actions that support the agreed medication plan and follow-up. It is patient-facing and should distinguish confirmed actions from recommendations that still need provider resolution.

An identified medication-related issue is acted on within professional scope or sent to the appropriate pharmacist, prescriber, or other provider. The urgency and recipient should match the potential risk.

They preserve what was found, what was communicated, who is responsible, and whether the issue was resolved. Without follow-up, a recommendation can remain an unclosed safety gap.

It must support optimum therapeutic outcomes through improved medication use and reduce the risk of adverse events, including adverse drug interactions.

An annual comprehensive medication review with a written summary in CMS's standardized format. The CMR includes an interactive consultation by a pharmacist or other qualified provider.

At least quarterly, with follow-up interventions when necessary. A targeted review addresses specific or potential medication-related problems and does not replace the annual CMR offer.

A transition of care can introduce changed, duplicated, stopped, or misunderstood therapies. Timely reconciliation and follow-up can identify discrepancies before they cause harm.

It should move ahead of routine outreach when delay could increase harm. Follow the escalation pathway, document the concern and time, and keep the case open until responsibility and follow-up are clear.

They show where each service or issue stands and help the team manage documentation, follow-up, and billing timelines. “Complete” should mean the required work and documentation are actually finished, not merely that outreach was attempted.